N

    Neuphoria Therapeutics Inc (NEUP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.76
    +0.00 (+0.00%)

    Market Cap: $20.32M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    69%(11/16)
    Avg Surprise
    -336.88%
    Streak
    2 Q

    Upcoming Estimates

    Jun 30, 2026
    EPS Consensus$-1.64
    Range$-1.64 - $-1.64
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    Sep 30, 2026
    EPS Consensus$N/A
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Sep 26EST
    		-N/A---
    Jun 26EST
    		-$-1.64---
    Mar 26
    		$-0.09N/A+83.93%Beat-101.4%
    Dec 25
    		$0.41$-0.56+173.21%Beat+133.2%
    Sep 25
    		$-4.41$-1.31-236.64%Miss-129605.9%
    Jun 25
    		$-5.55$-3.83-44.91%Miss-12600.2%
    Mar 25
    		$6.55$6.44+1.71%Beat+119.3%
    Dec 24
    		$-1.23$0.00N/ABeat-93.5%
    Sep 24
    		$-0.00N/AN/ABeat-
    Jun 24
    		$-0.04N/A+93.39%Beat-
    Mar 24
    		$-33.98$-0.58-5758.98%Miss-
    Dec 23
    		$-0.64$-0.63-1.19%Miss+4.0%
    Sep 23
    		$0.00N/A+100.00%Beat+100.0%
    Jun 23
    		$0.00N/A+100.00%Beat+100.0%
    Mar 23
    		$0.00N/A+100.00%Beat+100.0%
    Dec 22
    		$-0.66$-0.66-0.64%Miss-30.2%
    Sep 22
    		$-0.70$-0.70+0.11%Beat+13.6%
    Jun 22
    		$-97.20$-97.20+0.00%Beat-
    Mar 22
    		$-102.60$-102.60+0.00%Beat-
    Dec 21
    		$-0.51$-0.51+0.00%Beat-
    Sep 21
    		$-0.81$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-0.39EV/EBITDA-0.06x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin110513.00%
    ROE-62.90%ROIC-24.48%
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio14.31xQuick Ratio14.31x
    Trading Statistics
    BetaN/AAvg Volume51.44K
    52-Week High$21.4052-Week Low$3.19

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$3.87
    SMA 20$3.87
    SMA 50$3.82
    SMA 200$4.30
    EMA 10$3.83
    EMA 20$3.84
    EMA 50$3.95
    EMA 200$4.76

    MACD

    Line: -0.01Signal: -0.00Hist: -0.01

    ADX

    ADX: 22.4+DI: 21.2-DI: 16.0

    Aroon & PSAR

    Aroon Up64.0
    Aroon DownN/A
    PSAR$3.55

    Bollinger Bands

    Upper Band$4.00
    Lower Band$3.73
    %B Position687%(Upper)
    Band Width0.10

    RSI (14-Day)

    Neutral
    44.0

    Momentum Oscillators

    Stoch %K8.5
    Stoch %D12.0
    Williams %R-92.1
    ROC (10d)-2.3%
    Momentum-0.09
    CCI (20d)-136.6
    MFI (14d)40.1

    Volatility Measures

    ATR (14d)$0.17(4.6%)
    StdDev (20d)0.07
    Hist Vol22.7%(Moderate)

    Volume Flow

    VWAP$3.76
    OBV85.6M
    AD Line-56.8M
    CMF (20d)-0.446

    Volume Metrics

    Avg Vol (20d)51.1K
    Vol Ratio1.0x
    VWMA (20d)$3.90

    Pivot Points

    R3$3.94
    R2$3.89
    R1$3.82
    Pivot Point$3.77
    S1$3.71
    S2$3.66
    S3$3.59

    Advanced Oscillators

    TSI-2.19
    Ultimate Osc28.6
    KST42.89

    Financial Data

    QuarterMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Mar 2023
    Total Revenue$0$0$0$-13,267$15.00M$662,715$0$0$0$0$0$-44,717
    Cost of Revenue$0$165,789$165,792$7.98M$0$0$0$165,685$0$0$0$3.62M
    Gross Profit$0$-165,789$-165,792$-13,267$15.00M$662,715$0$-165,685$0$0$0$3.58M
    Operating Expenses$1.21M$6.08M$8.55M$5.82M$3.02M$4.37M$5.65M$5.48M$2.39M$4.55M$5.47M$7.37M
    R&D$-518,168$1.05M$5.73M$3.75M$1.62M$1.74M$3.79M$3.10M$1.20M$2.03M$3.09M$2.94M
    SG&A$1.69M$3.19M$2.82M$2.07M$1.41M$2.63M$1.87M$2.38M$1.20M$2.52M$2.38M$3.10M
    Operating Income$-1,211,649$-6,083,503$-8,551,953$-5,835,046$11.98M$-3,703,511$-5,652,689$-5,477,876$-2,394,031$-4,552,862$-5,467,607$-11,040,127
    Interest Income$186,171$167,311$141,996$87,046$12,741$30,615$141,996$26,327$52,615$54,716$86,439$0
    Interest Expense$0$0$6.49M$3.32M$796,218$0$4.29M$0$367,734$36,356$39,754$0
    Income Before Tax$-539,856$2.74M$-15,040,188$-9,150,259$11.18M$-1,931,740$-9,941,297$-2,721,142$-2,761,765$-4,589,218$-5,507,361$-5,314,821
    Income Tax Expense$-34,793$-52,124$-52,638$-266,602$-81,186$11,609$-34,793$-34,116$16,383$-34,794$-34,793$34,894
    Net Income$-505,063$2.79M$-14,987,549$-8,883,657$11.26M$-1,943,349$-9,906,504$-2,687,026$-2,778,148$-4,554,424$-5,472,568$-5,279,926
    EBITDA$-726,027N/A$-8,301,126$-9,071,680$11.33M$1.83M$-807,357$-2,583,419$-2,648,677$-4,478,240$-5,426,256$-5,681,542
    EBIT$-726,027N/A$-8,551,952$-9,237,305$11.17M$1.66M$-973,070$-2,749,104$-2,814,380$-4,643,934$-5,592,165$-5,837,171
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about NEUP

    News

    Neuphoria Therapeutics Inc (NEUP) Earnings Forecast: Future EPS & Revenue Growth Estimates

    Neuphoria Therapeutics Inc (NEUP) has an earnings forecast score of 6.00, placing it 327 out of 385 in the Biotechnology & Medical Research industry. Analysts have set an average price target of $20.00 for NEUP, with one analyst recommending a "Hold" rating. The company's EPS for the previous quarter was $0.41, significantly higher than the market expectation of -$0.09, while the next quarter's EPS is projected to be -$0.56.

    TradingKey•8/7/26•
    Somewhat-Bullish

    Are CBZ, SAFT, NEUP, TCBK Obtaining Fair Deals for their Shareholders?

    Halper Sadeh LLC, an investor rights law firm, is investigating CBIZ, Inc. (CBZ), Safety Insurance Group Inc. (SAFT), Neuphoria Therapeutics Inc. (NEUP), and TriCo Bancshares (TCBK) for potential violations of federal securities laws and breaches of fiduciary duties related to their proposed transactions. The firm encourages shareholders to contact them to discuss their rights, as insiders may receive substantial financial benefits not available to ordinary shareholders.

    PR Newswire•8/4/26•
    Somewhat-Bearish

    NEUP|Neuphoria Therapeutics Inc|Price:3.880|Chg%:-0.040

    This article provides a comprehensive stock analysis of Neuphoria Therapeutics Inc (NEUP) from TradingKey. It highlights the company's strong fundamentals and high growth potential, despite its stock trading sideways between support and resistance levels. The analysis also covers its valuation, institutional ownership, analyst ratings, and a detailed breakdown of its stock score based on various financial dimensions.

    TradingKey•8/1/26•
    Neutral

    Scancell merges with Nasdaq shell Neuphoria to fund USD 89m Phase III melanoma trial

    UK-based Scancell Holdings plc has announced an all-share merger agreement with Neuphoria Therapeutics Inc., a move that will provide Scancell with a Nasdaq listing and up to $89 million in financing. This funding is earmarked for the registrational Phase III development of Scancell's melanoma immunotherapy, iSCIB1+. The merger offers Scancell a faster route to US public markets and access to specialist oncology investors, despite Neuphoria's recent setbacks with its own drug candidates.

    AllSci•7/31/26•
    Neutral

    Neuphoria Therapeutics Inc (NEUP) Risk Assessment: Volatility, Financial Risk & Investment Risk

    This article provides a risk assessment for Neuphoria Therapeutics Inc (NEUP), noting its current score of 1.18, ranking 321 out of 384 in the Biotechnology & Medical Research industry. The company's beta of 0.73 indicates it tends to underperform during rising markets but experiences smaller declines in falling markets. The assessment includes detailed breakdowns of volatility, maximum drawdown, return metrics, and liquidity.

    TradingKey•7/30/26•
    Somewhat-Bearish

    Frequently Asked Questions About NEUP

    Does NEUP pay dividends?
    Neuphoria Therapeutics Inc (NEUP) does not currently pay a regular dividend.
    What is NEUP's market cap?
    Neuphoria Therapeutics Inc (NEUP) has a market capitalization of $20.32M with a current stock price of $3.76.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In